EBV-driven LMP1 and IFN-γ Up-Regulate PD-L1 in Nasopharyngeal Carcinoma: Implications for Oncotargeted Therapy.

Wenfeng Fang,Jianwei Zhang,Shaodong Hong,Jianhua Zhan,Nan Chen,Tao Qin,Yanna Tang,Yaxiong Zhang,Shiyang Kang,Ting Zhou,Xuan Wu,Wenhua Liang,Zhihuang Hu,Yuxiang Ma,Yuanyuan Zhao,Ying Tian,Yunpeng Yang,Cong Xue,Yue Yan,Xue Hou,Peiyu Huang,Yan Huang,Hongyun Zhao,Li Zhang

DOI: https://doi.org/10.18632/oncotarget.2608

2014-01-01

Oncotarget

Abstract:PD-L1 expression is a feature of Epstein-Barr virus (EBV) associated malignancies such as nasopharyngeal carcinoma (NPC). Here, we found that EBV-induced latent membrane protein 1 (LMP1) and IFN-γ pathways cooperate to regulate programmed cell death protein 1 ligand (PD-L1). Expression of PD-L1 was higher in EBV positive NPC cell lines compared with EBV negative cell lines. PD-L1 expression could be increased by exogenous and endogenous induction of LMP1 induced PD-L1. In agreement, expression of PD-L1 was suppressed by knocking down LMP1 in EBV positive cell lines. We further demonstrated that LMP1 up-regulated PD-L1 through STAT3, AP-1, and NF-κB pathways. Besides, IFN-γ was independent of but synergetic with LMP1 in up-regulating PD-L1 in NPC. Furthermore, we showed that PD-L1 was associated with worse disease-free survival in NPC patients. These results imply that blocking both the LMP1 oncogenic pathway and PD-1/PD-L1 checkpoints may be a promising therapeutic approach for EBV positive NPC patients.